<DOC>
	<DOCNO>NCT01283763</DOCNO>
	<brief_summary>The purpose study investigate non-inferiority topical Imiquimod therapy patient persistent CIN 2/3 compare standard therapy , i.e . conization A randomize , control , non-inferiority AGO-Austria trial</brief_summary>
	<brief_title>Topical Imiquimod Versus Conization Treat Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>Background : Alternatives surgery need treatment cervical intraepithelial neoplasia ( CIN ) . CIN associate persistent human papillomavirus ( HPV ) infection know potential precursor cervical cancer . The incidence CIN increase last decade , especially among young woman . Patients diagnose ( persistent ) high-grade CIN ( CIN2/3 ) treat conization . Conization regard safe procedure peri- postoperative complication ( infection , bleeding , preterm birth ) occur . This raise need conservative treatment alternative patient high-grade CIN . Preliminary data : Imiquimod ( IMQ ) , toll-like receptor 7 agonist , immune modulate substance approve therapy superficial skin lesion ( e.g . basalioma , actinic keratosis ) HPV associate disease ( e.g . anogenital condylomata acuminata vulvar intraepithelial neoplasia ) . In randomized , placebo-controlled phase II trial , previously show topical IMQ therapy efficacious feasible treatment select patient CIN 2/3 . Methods : In present open , randomize , non-inferiority trial 500 woman CIN 2/3 include . This non-profit , patient-oriented clinical research project conduct Austrian Gynecologic Oncology Group ( AGO-Austria ) trial . Participants randomize either 16 week treatment topical IMQ ( new treatment ) standard therapy i.e . conization ( active control ) . This study investigate non-inferiority new treatment , compare surgical standard treatment . The primary endpoint rate successful treatment , define negative HPV test result six month treatment start . Six month start therapy primary study endpoint assess use HPV genotyping . In addition clinical examination include colposcopy , HPV genotyping , cytology , indicate colposcopy-guided biopsy uterine cervix perform . In addition , rate CIN persistence/recurrence 6 , 12 , 18 , 24 month start treatment rate negative HPV test result 12 24 month start treatment evaluate treatment group . Rationale : The need conservative treatment modality patient diagnose CIN obvious , many young woman need surgical treatment . In randomized control , trial investigate non-inferiority topical IMQ treatment compare surgical standard treatment select patient diagnose CIN 2/3 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Inclusion criterion : 1 . Women age ≥18 year diagnose histologically verify CIN 3 woman age ≥ 30 year diagnose CIN 2 2 . Satisfactory colposcopy 3 . Signed informed consent 4 . Negative pregnancy test 5 . Appropriate contraception method fertile woman active study period 6 . Adequate compliance Exclusion criterion : 1 . Adenocarcinoma situ 2 . History previous conization 3 . Malignant disease time inclusion 4 . Colposcopy suspicious invasive disease 5 . Pregnancy lactation period 6 . Known allergy intolerance IMQ 7 . Contraindications conization IMQ 8 . Symptoms clinically relevant disease 9 . Known HIV infection 10 . Evidence clinically significant immunodeficiency 11 . Current , report participation another experimental , interventional protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cervical Intraepithelial Neoplasia , Imiquimod , conization</keyword>
</DOC>